雷珠单抗与康柏西普治疗湿性老年性黄斑变性的疗效对比

发布时间：2019-03-13 16:05

【摘要】：目的分析及比较对于湿性老年性黄斑变性实施雷珠单抗、康柏西普治疗的效果。方法选取2015年6月~2016年6月我院收治的湿性老年性黄斑变性患者60例,随机分成A组和B组,各30例。应用雷珠单抗治疗为A组,应用康柏西普治疗为B组,观察及统计经不同治疗方案以后获的效果。结果经治疗,同应用康柏西普治疗的B组相比较,应用雷珠单抗治疗的A组患者的视力更高,同时黄斑中心凹视网膜厚度更薄,差异有统计学意义(P0.05);进行注射4周和12周以后,对CNV渗漏的治疗两组均具有明显效果,差异有统计学意义(P0.05)。结论康柏西普治疗湿性老年性黄斑变性获得的CNV渗漏减轻效果同雷珠单抗治疗的效果相当,但是对于改善视力和黄斑中心凹视网膜厚度效果较差,随时间的增加,可达到疗效相同。
[Abstract]:Objective to analyze and compare the efficacy of Rayzumab and Compaximab in the treatment of wet age-related macular degeneration. Methods from June 2015 to June 2016, 60 patients with wet age-related macular degeneration were randomly divided into two groups: group A (n = 30) and group B (n = 30). Group A was treated with Rayzumab and group B was treated with Compaximab. The effects of different treatment schemes were observed and counted. Results after treatment, the visual acuity and retinal thickness of macular fovea in group A were significantly higher than those in group B treated with Compaximab (P0.05), and the visual acuity and retinal thickness of macular fovea in group A were higher than those in group B treated with Compaximab (P0.05). After 4 weeks and 12 weeks of injection, the treatment of CNV leakage in both groups had a significant effect, the difference was statistically significant (P0.05). Conclusion Compaximab can reduce the leakage of CNV in patients with wet age-related macular degeneration, but it is less effective in improving visual acuity and macular fovea thickness with the increase of time, and the effect of Compaximab is similar to that of Rayzumab in treating wet age-related macular degeneration. Can achieve the same curative effect.
【作者单位】：齐齐哈尔市第一医院病房西药局;
【分类号】：R774.5

【参考文献】